Web-based standard-regimen selection (SRS) and cancer-care registry (CCR) systems of a nationwide network in Japan: An attempt to improve breast cancer treatment.

2012 ◽  
Vol 30 (27_suppl) ◽  
pp. 76-76
Author(s):  
Kazuhiko Sato ◽  
Nobuaki Shinozaki ◽  
Masaru Iwai ◽  
Yoshio Mizuno ◽  
Rai Shimoyama ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Care ◽  
Chemotherapy Regimen ◽  
Current Treatment ◽  
Standard Regimen ◽  
Web Based ◽  
Nccn Guidelines ◽  
Patients With Cancer ◽  
Standard Chemotherapy Regimen

76 Background: Tokushukai group has a nation-wide network of 67 affiliated hospitals, and has started an “oncology project” to improve the quality of cancer care using web-based SRS and CCR systems. Methods: Every institution has been introduced the same electric-medical-record (EMR) to share the unified code to order chemotherapy regimens, and patient data could be collected on a database in the central office. 141 recommended regimens for 15 types of solid tumor have been approved in the cancer committee consisting of working-group and program-evaluation members. In breast cancer, 31 recommended regimens (7 for adjuvant and 24 for metastatic settings) were selected from the NCCN guidelines and approved by the committee. Not only recommended but also non-recommended regimens have their own specific codes in EMR, and the patterns of care in the selection of chemotherapy regimen were examined. Results: In 2011, 21 of 67 hospitals utilized these systems. 71.8% of 2,676 patients with cancer including 753 with colorectal, 317 with breast, 273 with gastric, 144 with non-small cell lung, 123 with pancreatic, and 73 patients with esophageal cancer had received 97 types of recommended therapies (11,022 cycles). In terms of breast cancer, 86% of 388 patients had been treated with recommended regimens (1,994 cycles). Among 71 patients received non-recommend therapies, only 6 patients (1.5%) had been treated with three regimens which were not regarded as standard regimens. Conclusions: The introduction of web-based SRS and CCR systems in a large medical group could facilitate standard chemotherapy regimen by an accurate examination of current treatment patterns.

scholarly journals Content of rehabilitation in the continuum of cancer care for patients in disease situations

2020 ◽  
Vol 19 (1) ◽  
pp. 60-64
Author(s):  
Alexandr B. Shmerkevich ◽  
Irina L. Krom ◽  
Marina V. Erugina ◽  
Diana D. Balakina
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Comparative Analysis ◽  
Cancer Patients ◽  
Cancer Care ◽  
Patients With Cancer ◽  
Working Age ◽  
The Continuum

Because of the optimization of the clinical and social prognosis of patients with cancer in recent decades, the possibility of incorporating rehabilitation in the continuum of cancer care is considered. Therefore, this study presents a comparative analysis of the quality of life among 427 working-age respondents with breast cancer in disease situations using the WHO QOL 100 questionnaire. Based on the results, a statistically significant decrease in the quality of life among the respondents in the physical and the level of independence spheres in the non-terminal situation of the disease was found, whereas in the group of incurable patients, a statistically significant decrease in the quality of life among the respondents in the physical, psychological, and level of independence spheres was found. Through the findings of this study, the rehabilitation of cancer patients in disease situations can be personified, and recommendations for improving the continuum of cancer care can be developed.

scholarly journals Considerations for the Management of Women with Breast Cancer during the COVID-19 Pandemic

2020 ◽  
Vol 5 (03) ◽  
pp. 260-263
Author(s):  
Monica Irukulla ◽  
Palwai Vinitha Reddy
Keyword(s):  
Breast Cancer ◽  
Resource Allocation ◽  
Patient Care ◽  
Cancer Patients ◽  
Cancer Care ◽  
Clinical Care ◽  
Current Availability ◽  
The Individual

AbstractOutcomes in cancer patients are strongly influenced by timeliness and quality of multidisciplinary interventions. The COVID-19 pandemic has led to severe disruption in cancer care in many countries. This has necessitated several changes in clinical care and workflow, including resource allocation, team segregation and deferment of many elective procedures. Several international oncological societies have proposed guidelines for the care of patients afflicted with breast cancer during the pandemic with a view to optimize resource allocation and maximize risk versus benefit for the individual and society. Clinicians may utilize these recommendations to adapt patient care, based on the current availability of resources and severity of the COVID-19 pandemic in each region. This article discusses the guidelines for care of patients afflicted with breast cancer during the pandemic.

scholarly journals ESMO 2020 update: Pancreatic cancer

2021 ◽  
Author(s):  
Elisabeth Sophie Bergen
Keyword(s):  
Pancreatic Cancer ◽  
Randomized Clinical Trials ◽  
Medical Oncology ◽  
Chemotherapy Regimen ◽  
Ductal Adenocarcinoma ◽  
First Line ◽  
Standard Chemotherapy ◽  
Trial Quality ◽  
Standard Chemotherapy Regimen

SummaryAt the ESMO (European Society for Medical Oncology) 2020 several interesting albeit not practice-changing studies in the field of pancreatic cancer were presented. The Canadian phase II randomized PA.7 trial investigated the additional benefit of dual checkpoint inhibition with durvalumab and tremelimumab to a standard chemotherapy regimen as first-line treatment in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Unfortunately, no significant improvement of responses or outcome could be achieved rendering this study a negative trial. Within the German platform-based QoliXane trial, quality of life was shown to be an essential prognosticator of survival with fatigue and nausea being independently associated with outcome of patients. Moreover, promising results could be observed with new targeted therapy approaches, which may lead to its investigation in larger randomized clinical trials.

The patient’s perspective of the quality of breast cancer care

2007 ◽  
Vol 43 (8) ◽  
pp. 1257-1264 ◽  
Author(s):  
Mascha de Kok ◽  
Rachel W. Scholte ◽  
Herman J. Sixma ◽  
Trudy van der Weijden ◽  
Karin F. Spijkers ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Care ◽  
Breast Cancer Care ◽  
Patient’S Perspective

On the Road to Improving the Quality of Breast Cancer Care

Medical Care ◽  
2008 ◽  
Vol 46 (8) ◽  
pp. 759-761 ◽  
Author(s):  
Jeanne S. Mandelblatt ◽  
Arnold L. Potosky
Keyword(s):  
Breast Cancer ◽  
Cancer Care ◽  
Breast Cancer Care ◽  
The Road ◽  
On The Road

Improving the organisation of breast cancer care increases quality of care while reducing costs

2004 ◽  
Vol 2 (3) ◽  
pp. 113
Author(s):  
G.L Beets ◽  
C.N.A Frotscher ◽  
C.D Dirksen ◽  
M.H Hebly ◽  
M.F von Meyenfeldt
Keyword(s):  
Breast Cancer ◽  
Quality Of Care ◽  
Cancer Care ◽  
Breast Cancer Care ◽  
Reducing Costs

scholarly journals The prophylactic and therapeutic effects of moxibustion combined with traditional Chinese medicine decoction for treating chemotherapy-induced myelosuppression in early-stage breast cancer: study protocol for a randomized controlled trial

Trials ◽  
2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Yajie Ji ◽  
Siyu Li ◽  
Xinyue Zhang ◽  
Yu Liu ◽  
Qing Lu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Chemotherapy Regimen ◽  
Early Stage ◽  
Controlled Trial ◽  
Early Stage Breast Cancer ◽  
Therapeutic Effects ◽  
Breast Cancer Patients ◽  
Randomized Controlled

Abstract Background Traditional Chinese medicine (TCM) has a long history of use in breast cancer, but lacking systematic evidence to support its clinical benefits. In this study, we evaluated the prophylactic and therapeutic effects of moxibustion combined with decoctions for treating chemotherapy-induced myelosuppression (CIM) in early-stage breast cancer patients. Methods This is a randomized controlled clinical trial single-blinded for TCM decoction but not moxibustion. Patients are equally divided into the control group without decoction and moxibustion treatment (control), the decoction+moxibustion group (MD), and the placebo+moxibustion group (MP), according to the following stratification factors: age (below 40s, 40s, 50s, and 60s or above), chemotherapy regimen (anthracyclines, taxanes, anthracyclines+taxane, and others), and chemotherapy strategy (adjuvant and neoadjuvant). The TCM decoction is Wenshen Shengbai Decoction. The anticipated sample size is 462 cases (154 cases in each group). All participants are expected to treat with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF). The primary outcomes include the proportion of patients with relief of leukopenia and/or neutropenia, the myelosuppression-associated serious adverse event including grade 3–4 leukopenia and/or neutropenia, and febrile neutropenia, and the dose of rhG-CSF. The secondary outcomes include chemotherapy adherence, stratified analysis, adverse reactions, quality of life by EORTC Breast-Cancer-Specific Quality of Life Questionnaire including EORTC QLQ-C30 (V3.0) and QLQ-BR23, TCM Constitution, and 3-year disease-free survival and overall survival. Baseline information including age, surgical approach, chemotherapy regimen and strategy, pathological stage, and molecular subtype will be recorded. Discussion This will be the first randomized controlled trial to evaluate the efficacy of moxibustion combined with TCM decoction in treating CIM in early-stage breast cancer patients, aiming to standardize the TCM decoction and moxibustion method, thus providing evidence for its clinical benefit. Trial registration chictr.org.cn ChiCTR-INR-16009557. Registered on 23 October 2016.

Sign in / Sign up

Export Citation Format

Share Document